Search

Your search keyword '"Hu, Shengshou"' showing total 1,247 results
Start Over Author "Hu, Shengshou"
1,247 results on '"Hu, Shengshou"'

7. Interpretation of Report on Cardiovascular Health and Diseases in China 2022

Author

MA Liyuan, WANG Zengwu, FAN Jing, HU Shengshou

Subjects
cardiovascular disease, epidemiology, health influencing factors, risk factors, prevalence, mortality, community-based prevention and control, rehabilitation, basic research, medical device development, fees, medical, Medicine
Abstract

Due to the acceleration of population aging and the prevalence of unhealthy lifestyles, the huge population with cardiovascular disease (CVD) risk factors, the burden of CVD continues to increase in China. CVD is still the leading cause of death among urban and rural residents in China. In 2020, CVD accounted for 48.00% and 45.86% of the causes of death in rural and urban areas, respectively, and two out of every five deaths were due to CVD. It is estimated that the number of current CVD patients in China is 330 million, including 13 million cases of stroke, 11.39 million cases of coronary heart disease, 8.9 million cases of heart failure, 5 million cases of pulmonary heart disease, 4.87 million cases of atrial fibrillation, 2.5 million cases of rheumatic heart disease, 2 million cases of congenital heart disease, 45.3 million cases of peripheral artery disease, and 245 million cases of hypertension. The total hospitalization costs were 270.901 billion yuan for CVD in China in 2020. The prevention and treatment of CVD in China still has a long way to go. In general, we should not only do a good job in secondary prevention and treatment of CVD, but also further strengthen the upstream treatment of modifiable risk factors such as hypertension, hyperglycemia and hyperlipidemia starting with both preventive treatment and treatment diseases. In addition, attention should be paid to the allocation and prioritization of health care and public health resources, so as to reach the inflection point of CVD prevention and treatment as early as possible.

Published
2023
Full Text
View/download PDF

32. Association of CYP2C19 genotypes with postoperative atrial fibrillation after coronary artery bypass surgery.

Author

Jiang, Qin, Huang, Keli, Han, Lizhu, Kong, Hong, Yang, Zhenglin, and Hu, Shengshou

Subjects
CORONARY artery surgery, BLOOD platelet aggregation, CORONARY artery bypass, CYTOCHROME P-450 CYP2C19, ATRIAL fibrillation, THROMBIN receptors, ORAL drug administration
Abstract

This cohort study aims to assess the connection between cytochrome P450 family 2 subfamily C member 19 (CYP2C19) genotyping, platelet aggregability following oral clopidogrel administration, and the occurrence of postoperative atrial fibrillation (POAF) after off‐pump coronary artery bypass graft (CABG) surgery. From May 2017 to November 2022, a total of 258 patients undergoing elective first‐time CABG surgery, receiving 100 mg/day oral aspirin and 75 mg/day oral clopidogrel postoperatively, was included for analysis. These patients were categorized based on CYP2C19 genotyping. Platelet aggregability was assessed serially using multiple‐electrode aggregometry before CABG, 1 and 5 days after the procedure, and before discharge. The incidences of POAF were compared using the log‐rank test for cumulative risk. CYP2C19 genotyping led to categorization into CYP2C19*1*1 (WT group, n = 123) and CYP2C19*2 or *3 (LOF group, n = 135). Baseline characteristics and operative data showed no significant differences between the two groups. The incidence of POAF after CABG was 42.2% in the LOF group, contrasting with 22.8% in the WT group (hazard risk [HR]: 2.061; 95% confidence interval [CI]: 1.347, 3.153; p = 0.0013). Adenosine diphosphate‐stimulated platelet aggregation was notably higher in the LOF group compared to the WT group 5 days after CABG (30.4% ± 6.5% vs. 17.9% ± 4.1%, p < 0.001), remaining a similar higher level at hospital discharge (25.6% ± 6.1% vs. 12.2% ± 3.5%, p < 0.001). The presence of CYP2C19 LOF was linked to a higher incidence of POAF and relatively elevated platelet aggregation after CABG surgery under the same oral clopidogrel regimen. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. The China Patient-Centred Evaluative Assessment of Cardiac Events (China PEACE)-Prospective Study of 3-Vessel Disease: rationale and design

Author

Rao, Chenfei, Bongiovanni, Tasce, Li, Xi, Gao, Huawei, Zhang, Heng, Li, Jing, Zhao, Yan, Yuan, Xin, Hua, Kun, Hu, Shengshou, Krumholz, Harlan M, Jiang, Lixin, and Zheng, Zhe

Subjects
Cardiovascular, Patient Safety, Prevention, Heart Disease, Clinical Research, Heart Disease - Coronary Heart Disease, Atherosclerosis, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, China, Coronary Artery Bypass, Coronary Artery Disease, Drug-Eluting Stents, Guideline Adherence, Humans, Patient-Centered Care, Percutaneous Coronary Intervention, Practice Guidelines as Topic, Prospective Studies, Quality Improvement, Quality of Life, Treatment Outcome, China PEACE Collaborative Group, Clinical Sciences, Public Health and Health Services, Other Medical and Health Sciences
Abstract

IntroductionComplex coronary artery disease (left main and three-vessel disease) carries high risks of adverse events and cost burden. However, in China, little is known about which patients are directed toward which treatment strategies and what outcomes are being achieved.Methods and analysisUsing the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) research network, this prospective study of three-Vessel Disease, the China PEACE-3VD study, has a plan to consecutively register over 4000 patients with a diagnosis of 3VD and/or left-main disease by elective coronary angiography at 24 large cardiovascular centres in China. We centrally conducted medical record abstraction and SYNTAX Score calculation for all registered patients. The sites invited patients to the prospective cohort, and conducted 1-year follow-up on major events, including cardiac events, symptoms, secondary prevention and quality of life. The estimated entire sample size of eligible patients of 4000 was determined based on both feasibility and consideration of adequate statistical precision for describing the treatment decisions, guidelines adherence and appropriateness of treatment for patients with complex coronary artery diseases. The study is designed to investigate patient, clinician and hospital factors associated with each treatment strategy (percutaneous coronary intervention, coronary artery bypass grafting or medical therapy) as well as appropriateness of treatment choice, current guideline compliance and patient-reported outcomes for patients with complex coronary artery disease in large cardiovascular centres in China, as a foundation for enhanced knowledge in the field and to assist quality improvement initiatives.Ethics and disseminationThe study protocol was approved by the ethics committee at the China National Center for Cardiovascular Diseases. Findings will be shared with participating hospitals, policymakers and the academic community, to promote quality monitoring, quality improvement and the efficient allocation, and use of coronary revascularisation procedures in China.Trial registration numberNCT01625312; Pre-results.

Published
2016

36. Versican Promotes Cardiomyocyte Proliferation and Cardiac Repair

Author

Feng, Jie, primary, Li, Yandong, additional, Li, Yan, additional, Yin, Qianqian, additional, Li, Haotong, additional, Li, Jun, additional, Zhou, Bin, additional, Meng, Jian, additional, Lian, Hong, additional, Wu, Mengge, additional, Li, Yahuan, additional, Dou, Kefei, additional, Song, Weihua, additional, Lu, Bin, additional, Liu, Lihui, additional, Hu, Shengshou, additional, and Nie, Yu, additional

Published
2023
Full Text
View/download PDF

37. Influence of Socioeconomic Gender Inequality on Sex Disparities in Prevention and Outcome of Cardiovascular Disease: Data From a Nationwide Population Cohort in China

Author

Wang, Yunfeng, primary, Tian, Aoxi, additional, Wu, Chaoqun, additional, Lu, Jiapeng, additional, Chen, Bowang, additional, Yang, Yang, additional, Zhang, Xiaoyan, additional, Zhang, Xingyi, additional, Cui, Jianlan, additional, Xu, Wei, additional, Song, Lijuan, additional, Guo, Weihong, additional, Wang, Runsi, additional, Li, Xi, additional, and Hu, Shengshou, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results